Prostate specific antigen mass ratio potential as a prostate cancer screening tool

Area of Science:

• Urology
• Endocrinology
• Biochemistry

Background:

• Obesity is linked to increased prostate specific antigen (PSA) levels, potentially due to hemodilution.
• However, obesity also affects prostate volume and insulin resistance, which can independently influence PSA.
• The combined impact of these obesity-related factors on PSA requires further investigation.

Purpose of the Study:

• To investigate the combined effects of body mass index (BMI), plasma volume, and insulin resistance on prostate specific antigen (PSA) levels.
• To evaluate the relationship between PSA, prostate volume, and obesity in Korean men.
• To determine the utility of PSA mass and PSA mass ratio as potential biomarkers in obese men.

Main Methods:

• Analysis of data from 3,461 Korean men aged 30-80 with available prostate volume measurements.
• Statistical analysis, including trend tests and ANOVA, was used to examine the associations between BMI, plasma volume, homeostatic model assessment index (HOMA-IR), prostate volume, and PSA.
• Adjustments were made for age and prostate volume to assess PSA mass and mass ratio.

Main Results:

• BMI positively correlated with plasma volume, HOMA-IR, and prostate volume.
• PSA showed a positive association with prostate volume and a negative association with plasma volume, but no significant association with HOMA-IR.
• Prostate specific antigen mass was associated with prostate volume, independent of plasma volume or BMI, while PSA mass ratio did not significantly change with BMI or plasma volume in older men.

Conclusions:

• Lowering PSA screening thresholds in obese men based solely on hemodilution is not supported.
• Obesity-related increases in prostate volume can elevate PSA levels, confounding screening.
• Alternative biomarkers, such as PSA mass ratio, may be necessary for accurate prostate cancer risk assessment in obese individuals.